Virogates A/S Feed

	Tid*
2025-11-06	12:00	Kvartalsrapport 2025-Q3
2025-08-21	12:00	Kvartalsrapport 2025-Q2
2025-05-01	12:00	Kvartalsrapport 2025-Q1
2025-04-24	N/A	Årsstämma
2025-03-20	N/A	Bokslutskommuniké 2024
2024-11-07	-	Kvartalsrapport 2024-Q3
2024-08-15	-	Kvartalsrapport 2024-Q2
2024-05-02	-	Kvartalsrapport 2024-Q1
2024-04-26	-	X-dag ordinarie utdelning VIRO 0.00 DKK
2024-04-25	-	Årsstämma
2024-03-21	-	Bokslutskommuniké 2023
2023-11-24	-	Extra Bolagsstämma 2023
2023-11-09	-	Kvartalsrapport 2023-Q3
2023-08-17	-	Kvartalsrapport 2023-Q2
2023-05-04	-	Kvartalsrapport 2023-Q1
2023-04-28	-	X-dag ordinarie utdelning VIRO 0.00 DKK
2023-03-23	-	Bokslutskommuniké 2022
2022-11-10	-	Kvartalsrapport 2022-Q3
2022-08-18	-	Kvartalsrapport 2022-Q2
2022-05-04	-	Kvartalsrapport 2022-Q1
2022-04-29	-	X-dag ordinarie utdelning VIRO 0.00 DKK
2022-04-28	-	Årsstämma
2022-03-23	-	Bokslutskommuniké 2021
2021-11-11	-	Kvartalsrapport 2021-Q3
2021-08-19	-	Kvartalsrapport 2021-Q2
2021-04-29	-	Kvartalsrapport 2021-Q1
2021-04-28	-	X-dag ordinarie utdelning VIRO 0.00 DKK
2021-04-27	-	Årsstämma
2021-03-24	-	Bokslutskommuniké 2020
2020-10-27	-	Kvartalsrapport 2020-Q3
2020-08-13	-	Kvartalsrapport 2020-Q2
2020-06-19	-	X-dag ordinarie utdelning VIRO 0.00 DKK
2020-06-18	-	Årsstämma
2020-04-30	-	Kvartalsrapport 2020-Q1
2020-03-25	-	Bokslutskommuniké 2019
2019-10-28	-	Kvartalsrapport 2019-Q3
2019-08-21	-	Kvartalsrapport 2019-Q2
2019-04-29	-	Kvartalsrapport 2019-Q1
2019-04-26	-	X-dag ordinarie utdelning VIRO 0.00 DKK
2019-04-25	-	Årsstämma

Land	Danmark
Lista	First North Denmark
Sektor	Hälsovård
Industri	Medicinteknik

2024-12-19 18:08:00 ViroGates publishes its financial calendar for 2025 12,10 DKK | -6,20%

2024-12-19 17:20:00 ViroGates announces financial guidance for 2025 12,10 DKK | -6,20%

2024-12-16 17:16:00 ViroGates announces a reorganisation of its marketing and sales department and revises its guidance for the year 13,10 DKK | 0,00%

2024-11-11 17:05:00 ViroGates’ capital raise of DKK 8.2 million and issue of 1,289,510 new shares have been registered 22,00 DKK | +46,67% | 2,70 MDKK

2024-11-07 12:05:00 ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth 9,80 DKK | +1,03% | 0,05 MDKK

2024-10-14 18:37:00 ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC 6,90 DKK | +25,45% | 0,92 MDKK

2024-08-15 12:30:00 ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers 6,40 DKK | +7,56% | 0,00 MDKK

2024-07-17 14:45:00 ViroGates announces revised financial guidance for 2024 6,10 DKK | +0,83% | 0,05 MDKK

2024-05-02 11:20:16 ViroGates announces its Interim Report for Q1, 2024: Quarterly revenue up 14% compared to Q1, 2023 6,20 DKK | -6,06% | 0,03 MDKK

2024-04-25 20:29:09 Resolutions from the Annual General Meeting of ViroGates A/S 6,50 DKK | -11,92% | 0,00 MDKK

2024-04-15 18:36:24 ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA 6,00 DKK | 0,00% | 0,19 MDKK

2024-04-10 13:46:41 ViroGates gives notice to convene the Annual General Meeting on 25 April 2024 6,66 DKK | +4,39% | 0,13 MDKK

2024-03-21 12:26:32 ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage 7,52 DKK | -0,27% | 0,15 MDKK

2023-12-21 16:25:48 Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S 7,18 DKK | -28,20% | 1,04 MDKK

2023-12-21 16:24:32 ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 7,18 DKK | -28,20% | 1,04 MDKK

2023-12-21 16:22:59 ViroGates publishes its financial calendar for 2024 7,18 DKK | -28,20% | 1,04 MDKK

2023-12-21 16:20:42 ViroGates announces financial guidance for 2024 7,18 DKK | -28,20% | 1,04 MDKK

2023-12-19 16:03:16 ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered 10,00 DKK | -31,74% | 0,15 MDKK

2023-12-15 10:58:39 ViroGates announces the outcome of its rights issue 8,00 DKK | +11,11% | 0,07 MDKK

2023-12-07 16:12:32 ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 6,24 DKK | +4,35% | 0,08 MDKK

2023-11-30 13:07:06 The subscription period in ViroGates’ rights issue begins today 6,38 DKK | +4,59% | 0,01 MDKK

2023-11-24 10:45:47 Resolutions from the Extraordinary General Meeting of ViroGates A/S 6,71 DKK | +6,62% | 0,09 MDKK

2023-11-09 12:11:20 ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 2023 10,80 DKK | -26,12% | 0,51 MDKK

2023-11-09 12:08:19 ViroGates announces an offering of new shares with pre-emptive rights for existing shareholders 10,80 DKK | -26,12% | 0,51 MDKK

2023-11-09 12:05:32 ViroGates announces its Interim Report for Q1-Q3, 2023: Revenue for the first nine months (Q1-Q3, 2023) was affected by a rough start to the year, despite Q3 itself represented Year-on-Year growth of 40% 10,80 DKK | -26,12% | 0,51 MDKK

2023-09-22 13:59:29 ViroGates announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis presented today at the European Shock Conference in Vienna, Austria 17,66 DKK | +11,71% | 0,32 MDKK

2023-08-17 11:38:54 ViroGates announces its half-year report for H1, 2023: Revenue is still negatively affected by lower-than-expected sales to clinical routine customers 14,73 DKK | -1,80% | 0,10 MDKK

2023-08-11 12:12:01 ViroGates announces its half-year report for H1, 2023 on 17th August 2023 and will host a webcast for investors 16,19 DKK | +1,45% | 0,07 MDKK

2023-06-02 16:05:46 ViroGates announces an agreement with Sobi for the development of suPARnostic® for commercial use in the US in combination with Sobi’s Kineret® treatment for COVID-19-related pneumonia 17,20 DKK | +7,21% | 0,03 MDKK

2023-05-17 16:03:03 ViroGates grants warrants to Denmark's Export and Investment Fund (EIFO) as the final step in fulfilling the requirements to obtain debt financing 16,89 DKK | +4,29% | 1,35 MDKK

2023-05-17 15:59:01 Sale of shares by majority shareholder in relation to terms for obtaining debt financing from Denmark's Export and Investment Fund (EIFO) 16,89 DKK | +4,29% | 1,35 MDKK

2023-05-04 13:03:50 ViroGates announces its Interim Report for Q1, 2023: Quarterly revenue declined by 67% compared to Q1 due to a longer ramp-up period in Emergency Departments 17,66 DKK | +19,90% | 0,14 MDKK

2023-04-27 20:33:39 Resolutions from the Annual General Meeting of ViroGates A/S 17,66 DKK | +1,78% | 0,08 MDKK

2023-04-12 15:07:38 ViroGates gives notice to convene the Annual General Meeting on 27 April 2023 21,13 DKK | -15,43% | 0,44 MDKK

2023-04-04 17:05:14 ViroGates announces preliminary results for Q1, 2023: Quarterly revenue affected by a slower-than-expected conversion of COVID-19 hospitals into use in triage in the emergency department 25,60 DKK | -24,37% | 1,02 MDKK

2023-03-23 17:20:20 ViroGates grants warrants to CFO Josephine Baum Jørgensen 36,47 DKK | -4,44% | 0,04 MDKK

2023-03-23 12:55:46 ViroGates announces its Annual Report 2022: Growing revenue by 33% and more than tripling the customer base in clinical routine 38,17 DKK | 0,00% | 0,07 MDKK

2023-02-24 11:34:55 ViroGates announces the commercial launch of its suPARnostic® POC+ product 43,95 DKK | +6,34% | 0,37 MDKK

2023-02-06 14:28:26 ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms 41,64 DKK | 0,00% | 0,09 MDKK

2023-02-01 13:24:57 ViroGates appoints Josephine Baum Jørgensen as its new Chief Financial Officer 39,33 DKK | +1,59% | 0,05 MDKK

2022-12-16 13:04:42 ViroGates publishes the financial calendar for 2023 32,46 DKK | -8,87% | 0,04 MDKK

2022-12-16 12:18:00 ViroGates announces adjusted financial guidance for 2022 and 2023 32,46 DKK | -8,87% | 0,04 MDKK

2022-12-06 13:33:18 ViroGates announces CFO Mark da Silva to step down during Q1 2023 38,48 DKK | -5,49% | 0,17 MDKK

2022-11-17 11:46:02 ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19 36,24 DKK | +7,55% | 0,34 MDKK

2022-11-10 13:00:08 ViroGates announces the emergency use authorisation of Kineret treatment for COVID-19 related pneumonia with a post-authorisation requirement on developing suPAR tests for commercial use in the US 31,23 DKK | +20,18% | 0,97 MDKK

2022-11-10 11:11:43 ViroGates announces its Interim Report for Q1-Q3 2022: 56% revenue growth 31,23 DKK | +20,18% | 0,97 MDKK

2022-10-05 14:26:54 ViroGates announces the publication of a new study that shows suPAR causes cardiovascular disease 23,83 DKK | +6,92% | 0,16 MDKK

2022-09-23 13:57:49 ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform 24,44 DKK | 0,00%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Virogates A/S

Prenumeration

Kalender

Beskrivning

Virogates A/S

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden